The purpose of the Histopathology Facility (HF) is to facilitate research conducted by investigators with peer-reviewed funding at FCCC by providing them with technical processing of cells and tissues as well as helping in the interpretation of results. The Facility's Technicians and Pathologist play a major support role in numerous research projects at the Center and their contributions have been and continue to be of paramount importance in the establishment and characterization of human cancer and other disease models. The Facility prepares, processes, and assists in evaluating tissues derived from experimental protocols developed by investigators with peer-reviewed funding. Most of the projects involve animal models of human cancer that require complex histological and/or cytological processing to determine morphological alterations, as well as to localize cancer-relevant gene products. The most frequently utilized services of the Facility include: laboratory animal autopsy, fixation, embedding and sectioning of paraffin-embedded tissues (7,000-8,000 per year), unstained paraffin sections for immunohistocnemistry (IHC) and LCM (10,000-14,000 per year), cryomicrotomy (100-200 per year), special stains (500-700 per year), immunohistochemistry (2,500-3,500 per year), in situ hybridization (100-200 per year), autoradiography (100-200 per year), digital microphotography (1,000-2,500 per year), and interpretative histopathology (7,000-10,000 HE and IHC slides signed-out per year). During the last CCSG funding cycle we have seen a significant increase in all services rendered as exemplified by the doubling in number of embedded and sectioned tissues (110% increase) and in the immunohistochemical work (120% increase). Furthermore, during 2000-2004 we implemented new technology such as tissue microarray sectioning and a Web-based Experimental Histopathology database. The Histopathology Facility also provides support to the Laboratory Animal Health Facility in quality control and animal health monitoring activities, as well as processing support to the Tumor Bank and the Research Cytogenetics and Laser Capture Microdissection Facilities. The HF is used by 33 investigators with peer-reviewed funding in 10 different Programs from all three Divisions. Eighty-nine percent (86%) of its use is for studies supported with peer-reviewed funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-46
Application #
7651437
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
46
Fiscal Year
2008
Total Cost
$174,111
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961
Araiza-Olivera, Daniela; Chernoff, Jonathan (2018) Hras helps hippo heterodimerize to evade tumor suppression. Small GTPases 9:327-331
Peng, Hongzhuang; Prokop, Jeremy; Karar, Jayashree et al. (2018) Familial and Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1 Deubiquitinase by Targeting Multiple Independent Domains. Cancer Res 78:1200-1213
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580

Showing the most recent 10 out of 1280 publications